Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:chemicalFormula |
C16H15ClF2N4O2S
|
| gptkbp:clinicalTrials |
Phase III
|
| gptkbp:contraindication |
pregnancy
lactation |
| gptkbp:developedBy |
gptkb:Genentech
|
| gptkbp:endOfLife |
approximately 50 hours
|
| gptkbp:firstAppearance |
2015-11-10
|
| gptkbp:formulation |
tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
cobimetinib
|
| gptkbp:interactsWith |
strong CYP3A inducers
strong CYP3A inhibitors |
| gptkbp:isATypeOf |
934660-93-2
|
| gptkbp:issuedBy |
oral tablet
|
| gptkbp:mandates |
BRAF V600E or V600K mutation-positive melanoma
|
| gptkbp:marketedAs |
gptkb:Cotellic
|
| gptkbp:numberOfStudents |
biliary
|
| gptkbp:sideEffect |
fatigue
nausea diarrhea rash elevated liver enzymes |
| gptkbp:targets |
gptkb:MEK2
MEK1 |
| gptkbp:triggerType |
MEK_inhibitor
|
| gptkbp:usedFor |
treatment of melanoma
|
| gptkbp:variant |
vemurafenib
|